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INTRODUCTION
For over two hundred years there has been documentation
of the extreme concern and quest for a method to restrain
cancer, a condition which has plagued both men and animals
(Karnofsky, 1948).

The primary obstruction to the control

and eradication of this class of disease has been the lack of
a thorough understanding of the mechanisms involved in neoplastic establishment, survival, and growth, although the
presence of tumor-specific transplantation antigens and an
immunocompetent host has been established (Smith, 1975).
A number of workers have observed the existence of a
fibrin investment early in the development of implanted and
spontaneously arising tumors (Hiramoto, 1960; Dvorak, 1979).
As early as 1878, Billroth detected tumor cells encased
inside a fibrin deposit (Zacharski, 1979).

Tumors have been

observed to possess the ability to stimulate the proliferation of host vessels to meet their metabolic needs in a
number of clinical and experimental systems including man,
mice, rats, and rabbits (Gimbrone, 1974; Folkman, 1975, 1976;
Auerbach, 1976; Gullino, 1978; Chodak, 1980).

Studies exam-

ining the vascularization of tumors have confirmed tumor
growth dependence upon a vascular supply (Folkman, 1976;
Gullino, 1981).

Experiments in which the tumor is physically

separated from other tissues demonstrate the tumor is still
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capable of stimulating vascular proliferation through the
barrier--supporting the theory that tumor cells release a
diffusible tumor angiogenesis factor (Folkman, 1976).

The

isolated tumor angiogenesis factor has mitogenic effects
upon capillary endothelial cells and can cause the formation
of tubular networks of blood vessel endothelial cells in
vitro (Folkman, 1980).

Although a vast amount of research

has been conducted in this area, numerous questions still
exist in the understanding of the relationship of tumor
establishment and growth.

RATIONALE
Previous experiments in the laboratory under the direction of Dr. Katherine K. Knapp looked at the effects of
sodium heparin upon the growth and morphology of implanted
spontaneous C3HjHeJ mouse mammary tumors.

These experiments

demonstrated that heparin anticoagulation was accompanied by
reduced tumor growth and vascularization (Knapp et al.,
1981).

The concept of tumor dependence upon angiogenesis

for growth has led to the proposal that a heparin-induced
alteration in the host's normal blood coagulation pathway
could modulate fibrin encasement of the tumor and circumvent
its establishment.

This was thought to be

a~complished

through a reduction in tumor vascularization as a result of
the decreased fibrin encasement of the tumor (Knapp et al.,
1981; Banaja, 1982).
Continuing the study of the relationships between
fibrin investment of the tumor, vascularity, and tumor
growth, we decided to investigate the relationship of warfarin sodium anticoagulation with tumor growth and vascularization.

It was reasoned that if the previously observed

altered tumor growth was due to heparin's anticoagulant
effect rather than a direct effect upon the tumor, another
anticoagulant with a different mechanism of action would
have the same tumor growth reducing capabilities.

Warfarin

sodium produces reduced fibrin pqlymer formation by a

3
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mechanism entirely different from that of heparin.

Hepar~n's

immediate anticoagulant activity results from a blockade of
thrombin's activity on fibrinogen, prevention of prothrombin
conversion to thrombin, and a reduction in platelet adhesiveness (Vigran, 1965; Gilman, 1980).

Warfarin's delayed

activity, however, is through an inhibition of vitamin K
activity leading to reduced synthesis of several clotting
factors (Gilman, 1980).

With the decision to use warfarin

sodium, experiments were designed to test the hypothesis
that a reduction or prevention of fibrin formation and thus
tumor encasement with this polymer would alter tumor growth.
It was also hypothesized that, accompanying the altered
tumor growth, several macroscopic factors including tumor
vascularization, extent of tumor attachment, vasodilation
of host blood vessels in the locale of the implanted tumor,
and local edema fluid would be altered.

Experiments were

conducted to determine the relationship between the dose
of warfarin sodium administered and the degree of alteration
of tumor growth and the related factors.

An inverse dose-

response relationship between dose of warfarin and tumor
growth and the related parameters was hypothesized.

LITERATURE SURVEY
Studies of Dvorak
Part of the foundation for our studies developed from
investigations conducted by Harold Dvorak and his associates
at Harvard University Medical School.

Using line 10 guinea

pig hepatocarcinoma and relying upon his observations from
these studies, Dvorak postulated that a tumor has the
capacity to promote its growth through the manipulation of
its host's clotting system (1979, 1979a).

Dvorak demon-

strated that the tumor cells released four factors which
have the capacity to effectively alter the host's immune and
infla~matory

mechanisms.

increase in vascular

These alterations entail an

permea~ility

in the tumor locale, stim-

ulation of blood coagulation, a stimulatory effect upon
plasminogen and inhibition of macrophage migration (Dvorak,
1979, 1979a).
The first factor distinguished was the vascular permeability factor (Dvorak, 1979, 1979a).

This factor was postu-

lated to contribute to the tumor's establishment of a fibrin
encasement by permitting the escape of plasma and thus
clotting factors into the area of the tumor (Dvorak, 1979,
1979a).

Its activity has been thought to be upon the capil-

lary endothelial cells (Dvorak, 1979, 1979a).

Further inves-

tigations demonstrated that this factor is not histamine.
5
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Prophylactic treatment with antihistamine showed a reduction
of vascular permeability, but the treatment possessed no
suppressive effects upon the tumor-released vascular permeability actions (Dvorak, 1979).

A tumor-released second

factor was identified as a procoagulation factor (Dvorak,
1979, 1979a).

Dvorak proposed that this factor also plays

a vital role in fibrin deposition around the tumor by potentiating thrombus formation, and by activating the clotting
factors which had migrated into the tumor area by virtue of
increased vascular permeability (Dvorak, 1979, 1979a).

The

third factor promoting tumor growth was a plasminogen activator (Dvorak, 1979, l979a).

This factor, Dvorak pointed

out, has been found to be associated with many malignant
cell types (1979).

It has been suggested that the plasmino-

gen activating factor may serve as a useful feature in
invasion

as a nonspecific protease (Dvorak, 1979).

The

third proposed activity of this factor was one of fibrinolytic activity for cocoon breakdown providing room for tumor
growth (Dvorak, 1979).

The fourth factor demonstrated by

Dvorak was a macrophage migration inhibition factor (1979,
1979a).

It is suggested that this tumor-mediated inhibitory

action may aid in the tumor's ability to block the host's
immunologic response and ultimate tumor destruction by
achieving a depression of macrophage migration to the area
of neoplastic development (Snyderman et al., 1976; Dvorak,
1979).

This factor has been explored in several other assays

along with those conducted by Dvorak and Snyderman (Green et

7

al., 1977).

Suggestions have been made that these four

mediators set the groundwork for a dynamic process of a
continuing reconstruction of the fibrin encasement, facilitating tumor growth (Figure I).
More recent studies have presented new evidence supporting Dvorak's procoagulant factor postulate.

Studies of

carcinomas in guinea pigs and mice have shown that these
carcinomas shed plasma membrane vesicles when cultured in
vivo or in vitro.

Dvorak reported that the vesicles con-

tained procoagulant and attributed the fibrin encasement
found around the carcinomas to the procoagulant produced
(Dvorak et al., 1981).
Tumor and C3HjHeJ Strain
While developing the protocol, it was decided that a
spontaneous tumor should be the source of the tumor implants.
Chemically-induced, virally-induced and passaged tumors are
known to differ

from spontaneously developed tumors both

in the antigens exhibited on their surfaces and in their
growth rates (Robbins, Angell, and Kumar, 1981).

Those

tumors which are chemically induced exhibit a heterogeneous
population of tumor-specific transplantation antigens on
their surfaces (Foulds, 1975).

Virally-induced tumors

associated with DNA or RNA viruses, display a homogeneous
population of tumor-specific transplantation antigens on
their cells' surfaces (Busch, 1974; Robbins, Angell, and
Kumar, 1981).

Yet, those tumors which arise spontaneously

demonstrate very few transplantation antigens.

Likewise,
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those tumors which frre continuously passaged grow much more
rapidly than spontaneous tumors (Robbins, Angell, and Kumar,
1981; Becker, 1977; Koller, 1960).

Thus, it appears that

those tumors which are not spontaneous in origin may be different from naturally developing tumors in· terms of growth
and host immune response.

Spontaneous tumors are therefore

preferred for research when clinical correlations are to be
suggested.
Mouse mammary tumors are widely used models for tumor
biology study (Greene, 1966).

The C3H inbred strain of

mice originated from a cross by Strong in 1920 of Bagg
albino mice and DBA strains of mice.

The strain was ex-

changed to Andervont in 1930 and exchanged again to Heston
in 1938 at F35.

The colony remained with Heston until 1947

when Jackson took over the colony at F48 (Inbred Strains of
Mice No. 10, July 1977; No. 4, July 1965).

C3HjHeJ female

mice exhibit a high incidence of spontaneously arising mammary tumors.

A 65 percent incidence of manrnary tumors is

reported in breeding females at age 6 months, while a somewhat lower incidence of 28 percent is observed in virgin
females at age 6 months (personal communication, Jackson
Laboratory, Bar Harbor, Maine).

The C3HjHeJ males have a

tendency to develop hepatomas and both sexes have relatively
low red and white cell counts (Inbred Strains of Mice,
No. 10, July 1973; Comp. to No. 57, July, 1977).

Breeding

statistics on the C3H/HeJ mouse report a breeding performance
in 1970 animals of 95 percent fertility with 4.2 litters per
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fertile dam, and an average litter size of 6.2 (Inbred
Strains, #6, Comp. No. 41, July 1969; No. 5, July 1967).
Fundamental Attributes of Neoplasia
In Pathophysiology:

The Biological Principles of

Disease, HenryS. Kaplan defined cancer as a".
category of disease .

generic

" emphasizing that although neo-

plastic g+owth is found in variable locations and cancer has
a variety of ways of expressing itself, there are fundamental
characteristics expressed which are unique to cancer cells
(Smith and Thier, 1981).

It is widely recognized that any

cell which belongs to a dividing cell population has tpe
potential to transform into a cancer cell (Smith and Thier,
1981).

Numerous studies have also supported the principle

that a cancerous mass results from the growth of one transformed cell (Isselbacher et al., 1980; Robbins, Angell and
Kumar, 1981; Smith and Thier, 1981).

Another major charac-

teristic commonly associated with tumor growth is the absence
of response to mechanisms controlling growth.

A neoplasm

does not necessarily grow more rapidly, a common misconception, but it simply does not stop expanding provided it
can meet its metabolic needs (Robbins, Angell, and Kumar,
1981).

Robbins, Angell and Kumar also point out that the

capacity for transplantation, the ability to grow in culture
without an anchorage, and the absence of contact inhibition
are relatively less common in normal cells which have not
undergone transformation (1981).

Investigations have also
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demonstrated that the biochemical changes associated with
most cancer cells are linked to the degree of the cancer
cell differentiation.

Those less differentiated cells

usually demonstrate characteristics which greatly deviate
from those of the normal cell population from which the
transformed cells arose (Robbins, Angell and Kumar, 1981).
Cells which are more differentiated are found to resemble
the biochemical nature of the cells of origin more closely
(Robbins, Angell and Kumar, "1981).
Another characteristic which is extremely important in
reviewing the features of neoplasia is invasiveness, typical
of all malignant tumors (Smith and Thier, 1981).

This

property is not necessarily accompanied by metastasis.

Inva-

siveness is the major property causing concern because it
permits the dissemination of malignant cells outside the
confinement of the original tumor (Smith and Thier, 1981).
Spread can occur directly into the body cavities, by penetration of the lymphatic system, or through hematogenous
invasion (Robbins, Angell and Kumar, 1981).

Thus, it is

understandable that a large amount of interest in experimentation centers around neoplastic invasiveness and metastasis.
Tissue Transplantation
Transplantation physiology is a topic closely associated
with immunology.

The interconnection of the two fields of

study stems from host recognition of antigens of the transplanted tissue.

Tumor cells possess specific antigens on
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their surfaces commonly known as tumor-specific transplantation antigens (Hyde and Patnode, 1978; Robbins, Angell and
Kumar, 1981).

These antigens are able to evoke an immune

response and some immunologists support the idea that through
immune surveillance the host is able to continuously mount

.

an immune-triggered rejection of tumor cells; however, under
~

some conditions the tumor cells are able to shield themselves
and escape elimination by the host (Hyde and Patnode, 1978;
Smith and Thier, 1981).
In experimental analysis employing implanted tissue,
several rules of transplantation must be remembered.

These

guidelines include isografts and tissues derived from inbred
strains or syngeneic animals, which are generally transplanted
successfully (Green, 1966; Guyton, 1981).
allografts,

or

Transplants of

tissues originating and implanted within a

species, usually enjoy a greatly reduced transplantation
success rate (Green, 1966; Guyton, 1981).

Green has also

noted that transplants arising from parents of an inbred
strain to Fl hybrids take, yet transplants from the Fl to
the parent are not successful (Green, 1966).

Clinical and

experimental examinations have shown that the more distantly
related the donor and host are, the greater the severity of
the immune rejection (Guyton, 1981).

Additionally, a possible

immune response to the tumor-specific transplantation antigens must be acknowledged (Robbins, Angell and Kumar, 1981).
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Blood Coagulation
Blood coagulation, under normal physiological conditions, involves a cascade of linked reactions resulting in
the activation of more than twelve clotting proteins and
requiring the participation of platelets and calcium.

These

components ultimately lead to the formation of a stable
fibrin clot.

The clotting proteins are synthesized in the

liver, and significant hepatic damage or vitamin K deficiency
greatly reduces their production and consequently greatly
influences blood coagulation (Isselbacher et al., 1980).
The clotting mechanism is composed of two pathways, the
intrinsic and extrinsic systems, either of which can cause
fibrin formation.

Although leading to the same final reac-

tions, the systems have

cert~in

distinctive characteristics.

The intrinsic system relies solely upon clotting factors
found within the circulating blood for its activity.

Upon

the appropriate stimulus the factors are sequentially activated leading to prothrombin conversion to thrombin which
initiates fibrinogen conversion to fibrin.

In the presence

of factor XIII, the fibrin-stabilizing factor, a stable
fibrin clot is formed.

Unlike the intrinsic system, the

extrinsic system is dependent upon clotting factor III,
tissue thromboplastin, for its activation.
not found in circulating blood.

This factor is

The clotting cascade reac-

tions, leading to the formation of a s·table fibrin clot,
occur much more rapidly, within seconds as opposed to minutes,
in the intrinsic system.

This rapid progression is achieved
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by skipping several reactions required in the intrinsic systern.

Eventually, both pathways result in factor X activation

and are identical from that point (Gilman et al., 1980)
(Figure II).
Pharmacologic Agent:
Warfarin Sodium
Traditional categorization places the anticoagulants into
two subdivisions.

These groups include those agents with

direct action, such as sodium heparin, and those agents with
indirect action such as 4-hydroxycoumarin.

The direct acting

anticoagulants are termed such due to their action both in
vivo and i.n vitro; whereas, those classified as indirectly
acting anticoagulants exhibit only in vivo activity (Wormser,
1978).

Three-(a-phenyl-B-acetylethyl)-4-hydroxycoumarin

sodium, more widely recognized by its generic and proprietary
names of warfarin sodium· and coumadin (Vigran, 1965), has an
interesting history.

Over 40 years ago both scientific and

lay observations began to accumulate which noted a relationship
between a hemorrhagic sweet clover disease affecting livestock,
prothrombin, the liver, and vitamin K (Vigran, 1965).

Frag-

ments of evidence evolved into an understanding of the nature
of anticoagulation which in turn led to the use of the developed soluble salt warfarin for rodenticidal purposes until
1953.

At this time Shepard Shapiro of New York suggested it

as a clinically useful medication (Vigran, 1965).
The coumarins exhibit no activity in vitro and only
minimal anticoagulant activity for at least 12 to 24 hours

16

Factor

Name

I

Fibrinogen

I '

Fibrin monomer

I"

Fibrin polymer

II

III

Prothrombin
Tissue Thromboplastin

IV

Ca 2 +, Calcium

V

Labile factor

VII
VIII
IX
X

XI
XII
XIII
PL

Figure IT.

Proconvertin
Antihemolytic Globulin, AHG
Christmas Factor, PTC
Stuart Factor
Plasma Thromboplastin antecedent, PTA
Hageman Factor
Fibrin-Stabilizing factor
Platelet Phospholipid

Common Synonyms of Blood Clotting Factors
(Modified from Gilman, 1980).
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following the initiation of a dosing regimen (Wormser, 1978).
Coumarin activity has been demonstrated within the liver
cell, with evidence suggesting it lies specifically within
the liver mitochondria enzyme systems (Vigran, 1965).

Spe-

cifically, coumarin results in a hindrance of hepatic synthesis of vital plasma clotting factors:

II, VII, IX, X.

This antagonism is accomplished through an inhibition or
antagonism of vitamin K activity and.transport (Suttie,
1979; Wormser, 1978; DeMeo, 1982).

Biochemical analysis

has shown that vitamin K is a necessary component of coagulation.

It serves as a coenzyme in some liver cell phosphory-

lation reactions in which coumarins effectively block the
phosphorylation (Vigran,· 1965).

Additional studies, examin-

ing the close resemblance of the chemical structures of 4hydroxycoumarin and vitamin K, have alluded to the possibility that this similarity may be key in the anticoagulant
activity of coumadin (Vigran, 1965), (Figures

III~

IV, V,

and VI).
The ultimate effect of warfarin sodium administration
is hypocoagulability.

This is achieved with a sequential

fall in plasma concentration of clotting factors VII, IX,
X, and II.

Maximum clotting factor depression does not occur

until 24 to 58 hours after the peak plasma concentration is
reached (Vigran, 1965).

Cessation of warfarin sodium therapy

results in a gradual return to the normal concentration of
plasma clotting factors, with a progressive increase in
factor II, X, IX, and eventually factor VII (Wormser, 1978),

18
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Figure III. Structural Formula of Warfarin Sodium.
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0

0

Vitamin K1
<Green Leafy Vegetables)

<Devlin~

Figure IV.

1982)

Structure and Origin of Vitamin K .
1
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0

0

Vitamin K2
<Intestinal Bacteria)
<Devlin~

__ ' _Figure V.

1982)

Structure and Origin of Vitamin K .
2
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0

0

Vitamin K3
(Synthetic - ~1enad tone)
(Devlin) 1982)

Figure VI.

Structure and Origin of Vitamin K3 .
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(Figures VII, VIII, and IX).

In man, this phenomenon

requires between one and two weeks (Vigran, 1965).
Goodman and Gilman report that in man, warfarin sodium
is metabolized in the liver.

Racemic warfarin in the circu-

lation is almost totally bound (99%) to plasma albumin during
the long-term therapy and following i.v. bolus administration
the half life in humans is 35 hours (O'Reilly et al., 1968;
Gilman et al., 1980).

The half life of warfarin sodium is

quite variable among species.

This variability is even seen

between sexes in normal Sprague-Dawley rats which exhibit a
mean plasma half life of 18 hours in males and 28 hours in
females ( 0' Reilly et al., 1968).

A few studies have been

conducted in mice, also revealing species variability in the
half life of warfarin sodium.

In May 1974 an investigation

of warfarin's influence upon blood coagulation by Neidner,
Kayser, and Meyer showed that mice require ten times more
warfarin per unit body weight to obtain the same anticoagulation as in a rat (Neidner et

~1.).

Neidner et al. also

found the half life of warfarin in mice to be 4.5 hours
(1974).

In a subsequent publication Neidner investigated

the serum protein binding of warfarin sodium in rats and
mice and reported.the half life of this agent as 1.9 hours
in the mouse with a cumulative LD50 of 25.0 mgjkg of warfarin
sodium, while the half life in rats was 19.5 hours and the
LD50 was 2.1 mgjkg (Neidner, 1974b).

Personal communication

with Gerhard Levy from the Department of Pharmaceutics,
Scqool of Pharmacy, State University of New York at Buffalo
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PRECURSOR

PROTHROMBIN

~
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1H2
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I
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2
PROTHROMBIN - CA + COMPLEX

PHOSPHOLIPID

v
THROMBIN

( DEVLIN & SUTTlE )

Figure IX.

Activity of Vitamin K in Clot Formation.
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confirms the extreme variability of warfarin's half life
even within the same animal strains.

Levy states that the

half life of warfarin within a single strain of rats differs
within a 30-fold range and that the half life of this agent
relates to protein binding, but the critical protein is not
albumin (personal communication).
Finally, as is understood with any pharmacologic agent,
both physiological and pathological factors can either
increase or decrease the response to oral anticoagulant
drugs.

These factors seldom affect the kinetics of accumu-

lation of the anticoagulant drug, but they do influence the
biological effect (Gilman et al., 1980).

Coumadin has also

been shown to demonstrate biologic actions other than anticoagulation.

These include vasodilation, bronchodilation,

and uricosuric effects (Vigran, 1965).

O'Reilly has also

shown that plasma warfarin, in humans, is found in an
unchanged form and warfarin metabolites are found in the
urine and stool (O'Reilly et al., 1968).
Vitamin K
Vitamin K naturally occurs as vitamins K1 in leafy green
vegetables and as vitamin K2 which is synthesized by intestinal bacteria.

The synthetic form of vitamin K, vitamin K3 ,

is known as menadione (Sebrell and Harris, 1954; Devlin,
1982), (Figures IV, V, and VI).

Until

quite recently, the

exact role of vitamin K in the hepatic formation of the
active clotting factors II, VII, IX, and X was not completely
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understood or verified.

Experimentation has suggested that

vitamin K is an essential component in the conversion of
prothrombin from its liver precursor (Suttie, 1979).

Spe-

cifically, vitamin K serves as a necessary cofactor in the
carboxylation of the glutamic acid residues to y-carboxyglutamic acid in the prothrombin precursor.

The y-carboxy-

glutamic acid residues of prothrombin bind Ca++.

A subse-

quent reaction occurs in which the ca++_bound prothrombin
complexes with a negatively charged phospholipid membrane
connecting the prothrombin to thrombin when associated with
active clotting factors V and X (Suttie, 1979; Devlin, 1982),
(Figure TX).
Previous Use of Heparin
Earlier investigations in our laboratory utilized
sodium heparin as the anticoagulant altering the fibrin
deposition around the tumor.

Sodium heparin administration

results in a hypocoagulable state through a route quite
different from that of warfarin sodium.

The mechanism of

action of heparin evolves around direct activity against
thrombin formation leading to reduced conversion of fibrinogen to fibrin.

This anticoagulant also prevents the activa-

tion of factor IX in the normal clotting design (Wormser,
1978).

Results from the studies at the University of the

Pacific School of Pharmacy revealed a significant reduction
of tumor growth in C3HjHeJ virgin female mice implanted
with spontaneous tumor cells and dosed with sodium heparin.
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These observations led to the suggestion

that

tumor growth

could be reduced by alteration of the fibrin cocoon encasing
it (Knapp et al., 1981; Banaja, 1982).
Clinical and Experimental Investigation
of the Relationship of Anticoagulation
and Neoplastic Growth
Accompanying the evolution of theories and observations
describing the presence of a fibrin encasement around a
tumor, several postulations pertaining to the role of a
neoplastic fibrin cocoon have been recorded.

Perhaps it is

the fibrin encompassing metastatic tumor cells which facilitates their establishment (Zacharski et al., 1979).

Other

hypotheses concerning the mechanism of action of the fibrin
cocoon propose that the role of the

~ncasement

lies in

nutrient provision or in stimulation of growth, with the
fibrin clot as the trellis for tumor growth (Zacharski et al.,
1979).

Others suggest that the cocoon may also serve as a

protective device disguising the tumor from immune surveillance of the host, or it is conceivable that a combination
of these proposals may qualify as an explanation of the
purpose of a tumor's fibrin encasement (Zacharski et al.,
1979).

These proposals have led to further questions regard-

ing the possible role of anticoagulation in neoplastic
management.

Numerous studies have revealed that hypocoagu-

lability, induced by heparin, the oral anticoagulants, and
ancrod (pit viper venom) may result in a decrease in tumor
.metastasis.

This decrease may also develop through hyper-
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fibrinolysis,

induced by plasmin and urokinase.

On the

other hand, observations have shown that hypercoagulability
and hypofibrinolysis may lead to a resultant increase in
metastasis (Hilgard, 1976), (Figure X).

These findings

suggest the pathophysiological significance of blood coagulation and also suggest a possible role of anticoagulation
as a viable tool for neoplastic growth control.
In their third edition Basic Pathology text Robbins,
Angell, and Kumar (1981) reported that the tumor's fibrin
encasement might provide protection for the tumor; however,
they felt that little or no clinical or experimental evidence
had been presented that would result in reduced metastases.
Evidence linking blood coagulation changes with neoplastic
development began to appear as early as the 1930's, with an
increase in studies beginning in the 1960's.

Preliminary

investigations on the effect of altered blood coagulation
dealt with animal test subjects.

In 1930, Alfred Goerner

presented the results of experiments which served as early
hints of an interrelationship between a modification in the
normal clotting mechanisms and a resultant change in tumor
growth response.

Goerner exposed rat carcinoma cells to

solutions conditioned with

0.1 percent sodium oxalate in

normal saline, 0.1 percent heparin in normal saline or normal
saline which served as the control.

Following various

degrees of exposure to the solutions, Goerner monitored in
vivo tumor growth finding no difference in tumor growth
characteristics with ten minute exposure.

Tumors exposed
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Hypocoagulability

I
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to the test solutions for three hours showed modest reductions in tumor growth while 22 hours of tumor cell exposure
revealed a large reduction in tumor growth in the oxalateconditioned tumor fragments and no observable tumors in the
heparin-treated group (Goerner, 1930).
The number of studies in this field rapidly multiplied
in the 1960's.

Eugene E. Cliffton, of the Sloan-Kettering

Institute for Cancer Research, and his associate, Domenico
Agostino, recognizing the importance of fibrin in metastasis
establishment, examined the effect of warfarin, heparin, and
fibrinolysin on lung metastasis in 1965.

Rats innoculated

with untreated normal carcinoma cells showed pulmonary
metastasis of 60 to 81 percent in a period of nine weeks.
Tumor cells exposed to heparin and 'fibrinolysis showed a
significant reduction in metastasis while the coumadin group
had a reduction, but to a smaller degree.

Their further

investigations have shown varying results; however, they
continued to point out the possibility that anticoagulants
may be feasible aides in treating cancer (Cliffton and Agostino, 1965).

In 1968 findings of a significant reduction

in metastasis in coumadin-treated mice were further substantiated by the experiments of Ryan, Ketcham, and Wexler (Ryan
et al., 1968).

One year later, in 1969, Ryan demonstrated

the effectiveness of warfarin when accompanied by removal of
the primary seeding tumor in reducing distant metastases in
mice (Ryan et al., 1969).
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In 1973 Brown and associates presented experimental
studies examining the effects of orally administered warfarin
sodium on sarcoma cell metastasis in syngeneic C3H mice.
Brown demonstrated that following the intravenous administration of a pre-determined number of neoplastic cells, warfarin
anticoagulation effectively reduced the number of lung
metastases at the very highly significant level.

Examina-

tions of lung metastasis of warfarin-treated mice following
thigh-implantations of sarcomas likewise showed some reduction in the number of developing lung colonies.

Tumor cells

possessing in vitro growth capabilities were placed in growth
medium later conditioned with warfarin.

Observations

revealed no cytotoxic capacity until the in vitro warfarin
sodium concentration was at a ten-fold level of the maximum
plasma concentration of warfarin in the test animals.

In

vivo studies of leukemic cells showed no significant difference in the TD50 between the control and test animals,
further supporting the postulations that warfarin lacks
cytotoxic and cytostatic properties.

Brown concluded that

warfarin anticoagulation might contribute to metastasis
reduction and that its activity was expressed through neither
cytostatic nor cytotoxic means (Brown, 1973).
In 1978 Adreina Poggi reported the results of a study
in which he investigated the effect of coumadin administration upon the formation of metastatic lung colonies subsequent to intravenous injection or intramuscular implantation
of syngeneic tumor cells in 350 mice.

Accompanying an
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effectively altered prothrombin time statistically significant inhibition and reduction in primary tumor and lung
colony development were seen yielding the conclusion that
reduced tumor growth and metastasis are achieved thr.ough
an impairment of the availability of vitamin K by coumadin.
More recently, Wattenberg has conducted studies on chemicallyinduced rat mammary tumors and mouse forestomach tumors and
demonstrated some growth inhibition by coumarin (Wattenberg
et al., 1979).

In 1981 Dvorak and associates presented

studies showing that some neoplasms may have procoagulant
activity in vesicles shed from their membranes.

It is

proposed that these may potentiate or be responsible for
the blood clotting activation and fibrin encasement observed
around a neoplastic growth.

This is in agreement·with

previously documented observations of tumor-associated procoagulation factor in guinea pigs and mice (Dvorak et al.,
1979 and 1981).
Studies investigating the possibility of clinical
applications of warfarin in cancer patients have been reported
by several researchers, including R. Douglas Thornes of the
Department of Experimental Medicine, Royal College of Surgeons, Ireland.

In 1961 Thornes began examinations of the

effective use of warfarin as an adjunct to traditional chemotherapeutic schedules.

Using the test patients as their

own controls, Thornes determined the level of response to
the added warfarin by the degree the chemotherapeutic agent
could be reduced while still holding the patient· in remission.
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Results showed response by 29 of the 96 patients and 21
patients responded with an average reduction of 25 percent
of the chemotherapeutic agent during a three month period.
!

Thornes advocated that oral anticoagulant adjunct therapy
be considered a viable tool in a chemotherapeutic regimen
( Thornes, 1972) .
Not all of the clinical investigations have shown anticoagulants supplementing traditional therapy to be beneficial
in improving or prolonging cancer patient survival.

In 1979

Stanford examined patients with small cell carcinoma of the
bronchus.

Twelve of the patients received warfarin and

heparin in conjunction with the cytotoxic drug treatment.
Stanford found that patients in the test group had a median
survival of 8. 85 mon.ths while those in the control group had
a median survival of 9.71 months (p > 0.05) (Stanford, 1979).
Thus, Stanford's conclusions contradicted Thorne's earlier
evaluations, emphasizing the requirement for more extensive
studies to fully evaluate the status of anticoagulants in
cancer therapy (Stanford, 1979).
Examination of the validity of suppl.ementing chemotherapeutic agents and radiation treatments with warfarin sodium
was pursued by Leo Zacharski and co-workers in a five year
Veterans' Administration cooperative study begun in April
1976.

The four year results followed the progress of fifty

patients positively diagnosed with small cell carcinoma of
the lung.
reKimen

Twenty-five of the patients were initiated on a

~upplemented

with warfarin sodium.

Zacharski found
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results favorable to the use of warfarin.

Those in the

control group, receiving only chemotherapy and radiation
therapy, showed a mean survival of 24 weeks; however,

the

25 test patients who received warfarin along with their
chemotherapeutic and radiation regimen showed a median survival of 50 weeks.

Demonstrable, but not significant, dif-

ferences were found in the time until relapse in the controls
(20.5 weeks) and the warfarin-treated patients (36.1 weeks).
Conclusions included the suggestion that fibrin does play
a role in tumor growth and metastasis, and the improvement
in survival times in patients receiving warfarin intimated
that warfarin may be beneficial in cancer therapy (Zacharski
et al., 1979 and 1981).
In Medical World News of March 1981, oncologist A.
Philippe Chahinian

of

Mount Sinai Medical Center, New York,

reported that the battle against tumor metastases, using
warfarin as the primary method of attack, had only begun.
Chahinian and the National Cancer Institute reported that
an international cooperative study involving 28 medical
centers was being developed to evaluate and hopefully aid
in the confirmation of the previous studies conducted by Leo
Zacharski.

The two year study is evaluating 250 cancer

patients, all receiving chemotherapeutic agents, half of
whom will have their therapeutic regimen supplemented with
warfarin.

Effectiveness of warfarin will be measured on the

basis of the time required for the detection of new metastatic
growths.

Chahinian feels that upon completion of this
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examination, the results of the Veterans' Administration
Cooperative Study will be confirmed and warfarin will be
seen as a valuable adjunct in the management of cancer
(Chahinian, 1981).
Tumor Angiogenesis
It has long been agreed that tumors possess the capacity
to induce their own vascularization (Auerbach, 1976).

This

understanding and the newly acknowledged idea that tumors
release a vascularization-inducing factor have involved
establishing the concept that inhibition of tumor angiogenesis may act as a mechanism in the control of tumor
growth.

In early attempts to explain what had been observed

with vascularized tumors, two ideas were proposed.
first suggested that. vessels

provid~ng

The

vascularization to

the tumor were dilated host vessels that were normally in
the area but which had been altered by a change in the metabolic requirements of the host in response to the tumor
(Folkman, 1976).

The second proposal suggested that these

vessels resembled those which are associated with inflammation (Folkman, 1976).

These proposals were considered quite

plausible until contributions by Greenblatt and Shubik (1968)
and later Folkman presenting experimental evidence that tumors
had the capability of inducing capillary proliferation in
healthy tissue from which they were physically separated
(Folkman, 1975 and 1976).

These observations exemplified an

evolving theory that a tumor released a humoral factor which
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could diffuse across a physical barrier and stimulate neovascularization (Folkman, 1976).

A 1971 report also pointed

out that Folkman's research team had successfully isolated a
tumor-secreted factor, known as a tumor angiogenesis factor
(Folkman, 1975).

Folkman had found this factor successful

in promoting vascular proliferation and capillary network
formation both in vivo and in vitro and had shown it capable
of inducing capillary endothelial cell mitosis (Folkman et
al., 1975 and 1980).

These breakthroughs led to the develop-

ment of the current tumor neovascularization proposal that a
tumor is able to contribute to the formation of its own
vascular supply by releasing a diffusible substance which
stimulates tumor infiltration by host blood vessels (Folkman,
1975).

Furthermore, this capacity of neovascularization not

only prOVides the tumor cells with their

nece~sary

n~trients

and method of eliminating their wastes, but may also provide
a means through which tumor growth may be controlled (Folkman, 1975).
Continued experimentation in this area has provided
new knowledge of the process which occurs during tumor vascularization.

Folkman and Gimbtone's study of tumor growth

employing the rabbit cornea assay has revealed that neoplastic
vascularization consists of two separate steps, the prevascular and vascular stages (Gimbrone et al., 1974).

In the

prevascular stage the tumors grow in a thin layer expanding
slowly; at the same time host vessels in the vicinity of the
slowly progressing tumor begin to grow toward the tumor,
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finally penetrating it.

Upon host vessel penetration of the

tumor, the vascular stage begins.

At this time the tumor

becomes well vascularized and rapidly expands (Gimbtone et
al., 1974).

These and numerous other examinations have

demonstrated the vital role vascularization plays in transforming a small dormant neoplastic mass into one which is
potentially lethal.
In conjunction with the tumor angiogenesis factor
hypothesis, many researchers have suggested that an interruption of blood vessel proliferation to the tumor would
alter tumor growth (Folkman, 1975; Maugh, 1981).

The method

by which this blockade can occur has been outlined by Folkman.

Folkman has proposed that there are four points at

which angiogenesis can be inhibited.

These include a pos-

sible attack on the tumor cell mechanism Which produces tumor
angiogenesis factor, resulting in reduced tumor angiogenesis
factor production.

Secondly, Folkman suggested designing

a method of finding a substance which would prevent the
passage of the tumor angiogenesis factor from the tumor to
the capillary endothelial cells.

A third block or obstruc-

tion would be achieved by reducing or abrogating the mitogenic
capacity of the tumor angiogenesis factor or by prevention
of the division of the capillary endothelial cells.

Finally,

Folkman proposed the prevention of tumor vascularization by
preventing capillary infiltration of the tumor (Folkman,
1974).

These proposals are being exposed to careful scruti-

nization and experiments have shown that the use of angiogenesis
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inhibition in regulating tumor growth is indeed valid
(Folkman, 1976; Maugh, 1981).

MATERIALS AND METHODS
Animals
The experimental protocol was designed to utilize
36 virgin female C3H/HeJ mice.

These animals were obtained

from Jackson Laboratory, Bar Harbor, Maine.

All mice were

relatively identical, i.e., 3 mo. to l year in age and
weighing from 18 to 30 grams.

While at the University of

the Pacific, all of the experimental and control mice were
maintained in metal cages with 12 mice per cage.

Bedding

was composed of processed natural wood fiber obtained from
K. C. Pharmacal, North Kansas City, Missouri.

The mice were

fed a high protein (not less than 20% crude protein) diet
in pellet form manufactured by Simonsen Laboratories, Inc.,
Gilroy, California, and watered, ad libitum, upon arrival
at UOP, with a continuance of this regimen for the duration
of the experiment.

During the experiment all of the mice

were housed in the UOP School of Pharmacy animal wing which
is maintained with a regular 12-hour lighting cycle with
lights on at 6:00AM and off at 6:00PM.

Temperature is

.held within the standards recommended by the Institute of
Laboratory Animal Resources of 18-29° C (± lOC).
Tumor
The tumor used for implantation into the 36 experimental mice was a spontaneously developed C3HjHeJ mouse
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mammary tumor.

The tumor-donating mouse was given to our

laboratory by Larry Young, Department of Pathology, University of California at Davis, School of Medicine.
Pharmacologic Agent and
Dosing Regimen
The pharmacologic agent used in this study was injected
warfarin sodium (coumadin), purchased from Endo Laboratories
(Garden City, New York).

The anticoagulant was obtained in

single injection units which were reconstituted, properly
diluted and immediately injected.

The crystalline warfarin

sodium and the solutions for injection were reconstituted
and diluted using sterile water for injection, u.s.p.
(pH 5.0- 7.0).

All solutions were thoroughly mixed before

and after preparing the dilutions to insure that an appro~riat~

coricentration of the solution was obtained for further

dilutions.

Serial dilutions of the reconstituted solution

yielded a solution of 0.75 mgjkg, high dose, and 0.15 mgjkg,
low dose, warfarin sodium.
The 36 animals were divided into three groups of 12
each.

Two groups of experimental C3H/HeJ virgin females

were treated with warfarin sodium.
received daily doses of 0.75 mgjkg

Group A, high dose,

i·E·

warfarin sodium;

Group B, low dose, received daily injections of 0.15 mgjkg

!·E·

warfarin sodium.

A daily injection regimen was insti-

tuted five days prior to the tumor implantation with daily
(5 PM) administration of the agent continued for the duration
of the experiment.

Animals belonging to Group C, controls,
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were treated daily with sterile, nonpyrogenic lactated
Ringer's injection, u.s.p.

This regimen was initiated five

days prior to tumor implantation and, likewise, continued
with daily administration for the duration of the experiment.
Upon

inject~on,

each animal was weighed on a top-loading

balance and point body weight doses of the appropriate solutions were injected,

l·E·

Injections were performed using

disposable insulin syringes with 14.7 mm needles.

Extreme

care was taken not to puncture the bladder or the intestines
with the injection needles.
Animal Identification
Each animal received an anatomical label to aid in
accurately determining the percent of original tumor implant
present at sacrifice.

This was accomplished by swabbing.

the appropriate area of the mouse with a saturated solution
of picric acid.

This method proved effective for identifi-

cation of individual mice in each group for the duration of
the experiment.
Tumor Preparation
The animal providing the large, solid, and highly
vascularized spontaneous C3HjHeJ tumor was sacrificed by
overetherization in a hard plastic dessicator, adapted to
an ether chamber for experimental purposes.

The skin cover-

ing the tumor was cleansed with alcohol to prevent hair
from contaminating the surgical field.

A postmortera.dis-

section of the tumor area was performed with autoclaved
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surgical instruments; removal of the overlying skin exposed
the tumor.

The tumor mass was excised and large sections

were placed in petri dishes filled with cold lactated Ringer's
solution.

Using sterile surgical instruments, the tumor

pieces w·ere washed in the cold Ringer's and placed in clean
Ringer's solution for sectioning.

Working quickly to insure

maximum tumor cell viability, cleaned tumor pieces were
further cut into sections 0.0114 ± 0.00035 grams (mean ± SEM)
in size.

The transplantation-size tumor pieces were trans-

ferred into fresh Ringer's solution for subsequent implantation into the experimental and control animals.
Tumor Implantation
At time zero, all 36 animals received finely minceq
subcutaneous implants of C3HjHeJ spontaneous mouse mammary
tumor 0.0114 ± 0.00035 grams (mean± SEM).

The following

procedure was employed for each mouse in the experiment:
l.

the mouse was lightly anesthetized in an ether
chamber;

2.

in preparation for tumor implantation, an individual piece of sectioned spontaneous mouse mammary
tumor was weighed and the weight recorded.

As

noted earlier, each mouse was labeled for future
reference as to tumor implant weight;
3.

the anesthetized mouse was placed on a dissection
board and held by the tail and the nape of the
neck, slightly stretching the dorsal skin, while
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leaving the dorsal surface exposed.

The skin over-

lying the base of the tail on the dorsum was rinsed
with alcohol and a l/4" incision was cut with
scissors through the skin;
4.

a 13-gauge wide-bore trocar, loaded with a previously weighed tumor, was inserted through the
incision and the end guided to the dorsal side
of the left shoulder;.

5.

following placement of the trocar in the desired
location a rod was inserted inside the barrel of
the trocar, expelling the tumor implant at the
desired site caudally to the left shoulder;

6.

the trocar was withdrawn and the incision pinched
closed.

The entire

i~plantation

pr6cedure involves

only approximately 15 seconds for each mouse.
No problems with infections have been experienced.

Following

each implantation, the animals were placed in a separate cage
and observed until they had recovered from the procedure.
Experimental Schedule
A synopsis of the experimental schedule is presented in
Table l.

The experiment began five days prior to tumor

implantation with the initiation of the drug administration,
as discussed previously.

On day 0, all 36 of the experi-

mental and control mice were implanted with pre-weighed
spontaneous C3H/HeJ mouse mammary tumor pieces.

Twenty-four

hours after the tumor implantation, three mice from each
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Table I
Experimental Schedule

Implantation
(T = 0 hr.)

CONTROL
Ringer's

(N

=

12)

B

A

Warfarin
Sodium

Warfarin
Sodium

High Dose

Low Dose

(N

=

12)

(N

=

Sacrifice

1 day

3*

2 day

3

3

3

.. 3

3

4 day

3

3

3

8 day

3

3

3

*Indicates the number of mice sacrificed at each day.

12)

4:6

experimental group were sacrificed.

This procedure was

repeated on day 2, day 4, and day 8.
$acrifice Protocol
At each indicated sacrifice time, several observations
and examinations were performed.

These included:

a deter-

mination of whole blood clotting times; sacrifice of each
animal; photography of each tumor; rating of local vascularity, vasodilation and edema fluid; and the extent of
tumor attachment.

The tumors were excised, weighed, and

placed in formalin for fixation.
Whole Blood Clotting Time
Determinations
Prior to sacrifice, the whole blood clotting time was
determined for each mouse using the
clotting time method (Vigran, 1965).
anesthetized with diethyl ether.

Le~

White whole blood

The mice were lightly

Using non-heparinized

microhematocrit capillary tubes, a periorbital puncture was
performed and one tube (0.7 cc) of whole blood collected.

A

stopwatch recorded the time the blood entered the capillary
tube and was kept running until a clot had formed.

Clot

formation was observed by tilting the capillary tube, end
to end, every thirty seconds.

When the blood ceased flowing

scores were made in the capillary tube and it was broken
every thirty seconds until a clot had formed and stretched
across the break in the capillary tube.

This time was

recorded as the whole blood clotting time.
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Sacrifice and Macroscopic
Evaluations
Following the whole blood clotting time determination,
the mice were sacrificed by overetherization.

The mice were

placed on dissection boards and their dorsal sides were
washed with alcohol to prevent hair from entering the field.
A midline dorsal incision was performed and the dorsal skin
pinned back to expose the tumor.

The superior epigastric

and external thoracic veins and their branches were examined
on the tumor side and the opposite side of the mouse to
determine the presence or absence of vasodilation.

Vascu-

larity in the area of the tumor was determined by counting
the number of vessels approaching the tumor.

The criteria

for the vascularity ratings are presented in Table II.

The

immediate vicinity of the tumor was examined for the presence
or absence of local edema fluid.

Each tumor and its sur-

roundings were photographed with a 50 mm macro lens to allow
later observations and for illustrative purposes.

The final

procedures involved excising each tumor, observing and
rating the extent of attachment, as illustrated in Table III,
and weighing the tumor.

Following weight determination each

tumor was fixed in formalin.
Statistics
The percent of the original tumor mass present at sacrifice was calculated by dividing the tumor sacrifice weight
by the tumor implant weight and multiplying by one hundred.
Whole blood clotting times, percent of original tumor mass,
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Table I I
Rating Criteria for Vascularity
in the Locale of Tumor

1 -

No;

No Vessels Present

2 -

Vessels in the area

3 -

+·
'
++;

4 -

+++;

Countable ( < 5) to tumor
Uncountable ( > 5) to tumor
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Table III
Attachment of Tumor Rating Criteria

1 -

No;

2 -

+·

3 -

++;

4

'

+++;

Edema

no attachment
pulls out
cut out
cut out leaving gouge in skin

Flu~d

& Local Vasodilation
Evaluation

Present or Absent
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vascularity and attachment ratings were evaluated for significance between the means by the Dunnett's t test.

Evalu-

ations of the presence or absence of edema fluid and local
vasodilation were inspected for significance between the
control and each warfarin sodium group by employing the ChiSquare test for significance between two groups of quantal
data.
mean.

All means were reported ± 1 standard error of the

RESULTS
1.

Whole Blood Clotting Time
Intraperitoneal injection of high dose, 0.75 mgfkg,

warfarin sodium in Group A was associated with a significant
prolongation (p < 0.05) in whole blood clotting time in
comparison to the control group (Table IV, Figure XI).

Mice

receiving 0.75 mgjkg warfarin sodium had a mean clotting
time of 392.7 ± 16.9 seconds, whereas those mice receiving
daily injections of lactated Ringer's solution exhibited mean
clotting times of 161.4

± 26.7 seconds.

The mice in Group B,

0.15 mgjkg (low dose), warfarin sodium also showed a prolonged clotting time with respect to those in the control
group.

This prolongation was not statistically significant.

The mean whole blood clotting time for Group B mice was
228.9 ± 33.7 seconds (Table IV, Figure XI).
2.

Tumor Weight
Animals in the high dose, 0.75 mgjkg, warfarin sodium

group showed a significantly reduced (p < 0.05) percent of
original tumor weight upon sacrifice when compared to the
mean percent of original tumor weight in the control group
at sacrifice.

The mean percent of original tumor weight in

Group A at sacrifice was 30.67 ± 4.75 percent.

Those mice

receiving low dose warfarin sodium showed a nonsignificant
trend towards a reduction in percent of original tumor weight
51

Table IV
Summary of mean tumor implant weights (in grams), whole blood clotting times
(monitored in seconds), and the percent of the original tumor weight as
observed in the high dose (0.75 mgjkg), low dose (0.15 mgjkg) warfarin
sodium and control (lactated Ringer's solution) groups

Warfarin Sodium
Parameter
Investigated
Tumor Implant
Weights (g)
Whole Blood
Clotting Times
(seconds)

% original

Control

Group A

Group B

High Dose

Low Dose

0.0127 ± 0.00062a,*
392.7

30.67

±

16.9

±

4.75

0.0106 ± 0.00050
228.9

43.08

33.7

±

±

2.70

Group C

0.0109 ± 0.00056
161.4

58.98

±

26.7

±

8.72

tumor weight

aN = 12 for all except High Dose Warfarin Sodium Whole Blood Clotting Time
with N = ll.
*Mean ± S.E.M.
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when compared to the control group.

The mean percent of

original tumor weight observed in Group B at sacrifice was
calculated as 43.08 ± 2.70 percent.

Mice dosed with Ringer's

solution, the control group, demonstrated a mean of 58.98 ±
8.72 percent of the original tumor mass on the sacrifice
days (Table IV, Figure XII).
3.

Vascularity in the Locale of the Tumor
Mice receiving 0.75 mgjkg warfarin sodium exhibited a

significant (p < 0.05) reduction in the amount of vascularity in the locale of the tumor.

Vascularity ratings for

this group were 1.90 ± 0.314 while the mean vascularity
rating for the control mice was 3.42 ± 0.229.

Group B, low

dose warfarin sodium, showed a minimal, but not significant,
reduction in tumor vascularity with a mean rating of 2.00 ±
0.302 (Table V, Figure XIV).
4.

Tumor Attachment
Tumor attachment was found to be significantly reduced

(p < 0.05) in both the high and low dose warfarin sodium
groups.

The high dose warfarin sodium group demonstrated

a mean tumor attachment rating of 1.67 ± 0.284 while those
mice in the low dose warfarin sodium group had a mean tumor
attachment rating of 2.75 ± 0.250.

Mice in the control

group demonstrated a mean attachment rating of 3.67 ± 0.142
(Table V, Figure XIII).

56

I

J

!::,..,
. ;:)
{

T

I
I

100

I

A: p < 0.05
8: N.S.

(/)
(/)

0

~
~

60

I
. I

( \

I
I
I
I

""
\
'\c

I
I

I

~

~1: /·

E
~

I

I

I:

0

c

I
I~
I

-:;..

·0'\

t\...

~

0

10

I

I

I
I
I
I

80

0

T

40

I

~
IX

J.

I:
Ii

-

~
~
~

ll

-:;.

I:
I'

~

-:;.

'
J.i

~
~

..
\

~
~

..

~

i...

\

~
T

\

\\\\\

I

~
<#

,,,,

I

,,,,,

I

~ I
~:

~

,,,,

I

~

~

,,,,,,,

I

"!.

I

\\\\\\

l

~

20

'
'

A

\\\

,,,,,,,

\\\\\

"''''
I

2

4

Time (Days)

8

Table V
Vascularity and attachment evaluations, observed in high dose (0.75 mgjkg)
and low dose (0.15 mgjkg) warfarin sodium and control groups

:warfarin Sodium
-~

Parameter
Investigated

-

-~-------

------

High Dose

-

Control

Low Dose

Local Vascularity
Rating

1.90 ± 0.314a,*

3.00 ± 0.302

3.42 ± 0.229

Attachment Rating

1.67 ± 0.284

2.75 ± 0.250

3.67 ± 0.142

aAll N

= 12 except High Dose Warfarin,Sodium vascular rating with N = 10.

*Mean ± S.E.M.
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5.

Local Vasodilation
Local vasodilation evaluations revealed a significant

reduction (p < 0.025) in vasodilation of vessels near the
tumor in group A, with only 50% of these mice showing the
presence of vasodilation.

A trend towards a reduction (not

significant) in vasodilation was seen in the low dose warfarin sodium group.

Eleven of twelve or 92% of the mice

in the low dose group demonstrated local vasodilation.
All mice in the control group showed local vasodilation
(Table VI).
6.

Edema Fluid
Evaluations of the presence or absence of edema fluid

around the tumor again demonstrated a significant

reduc~ion

(p < 0.01) in edema fluid in the mice treatedwitha high
dose of warfarin sodium.

Only 30% of the tumors in this

group had edema fluid around the tumor.

Again, only a mini-

mal nonsignificant reduction in edema fluid was seen in the
low dose warfarin sodium group with 92% of the tumors having
edema fluid.

The control mice demonstrated the presence of

edema fluid in 100% of the mice (Table VII).
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Table VI

Local vasodilation ratings in high dose (0.75 mgjkg),
low dose (0.15 mgjkg) warfarin sodium and control
groups evaluated as a ratio of the number of
positive responses to the total
number of examinations

Number of
Positive/Total
Number Examined

High Dose

Percent
Positive

5/10

50

ll/12

92

12/12

100

Warfarin Sodium
Low Dose

Control
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Table VII

Edema fluid ratings in high dose (0.75 mgjkg),
low dose (0.15 mgjkg) warfarin sodium and
control groups evaluated as a ratio of
the number of positive observations
to the total number of examinations

Number of
Positive/Total
Number Examined

Percent
Positive

High Dose

3/10

30

Low Dose

ll/12

92

12/12

100

Warfarin Sodium

Control

DISCUSSION
This study has shown that there is a significant reduction in the percent of original tumor mass compared to
control animal tumor growth when warfarin sodium is administered at a dose of 0.75 mgjkg.

Reductions were also noted

in the group receiving low dose (0.15 mgjkg) warfarin sodium;
however, these reductions were not significantly different
from the control group.

Observations of the low and high

dose warfarin sodium groups showed a trend towards a reduction in all of the variables examined in the low dose group
and an even greater reduction in the tumor weight, vascularity, and attachment parameters in the high dose group.
response

~orrelations

Dose-

can be suggested which relate the

alteration of vascularization and tumor growth in the test
animals.
Our experiments demonstrated that with the daily
administration of a high dose of warfarin sodium (0.75 mgjkg)
significant reductions in tumor growth could be observed
(Table IV, Figure XII).

It has been postulated by other

workers that an induction of a state of anticoagulation
would reduce the amount of tumor growth through a reduction
in the tumor's fibrin encasement (Lock, 1971; Zacharski et
al., 1979; Brown, 1973).

This idea has also been demonstrated

in previous studies conducted by Brown and Zacharski (Brown,
1973; Zacharski et al., 1979, 1981).
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Several factors must be considered when speculating why
an alteration in fibrin investment of a tumor may lead to
reduced tumor growth.

It is conceivable that the reduction

in tumor growth is not attributable to the altered fibrin
formation, but the reduced tumor growth is due to warfarin's
cytotoxic effects upon the tumor cells (Thornes, 1972).
Although a plausible explanation, J. Martin Brown demonstrated that warfarin possessed no cytotoxic activity towards
KHT cells in vitro (Brown, 1973).

Previous studies using

sodium heparin in C3H/HeJ mice noted mammary tumor growth
reduction in anticoagulated animals (Knapp et al., 1981).
Since heparin anticoagulates by a mechanism different from
warfarin, those results in conjunction with ours suggest
that the"anticoagulation is affecting tumor growth rather
than acting through a cytotoxic mechanism upon the tumor
cells.
This coat removal or reduction may lead to a variety
of situations in which the tumor has reduced capacity to
grow.

Some researchers believe the fibrin encasement pro-

vides a physical barrier, c9ncealing the developing tumor
from the host's immune surveillance (Dvorak et al., 1979,
1981).

Specifically, the fibrin coat may shield the tumor-

specific transplantation antigens from detection by the
host's immune system.

The fibrin coat may prevent lympho-

cytes, involved in tumor surveillance, from reaching the tumor
(Dvorak et al., 1979, 1981).

If the fibrin encasement is

not surrounding the tumor then it is possible that the tumor
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could be detected by the host; the tumor-specific transplantation antigens may be detected by the host's lymphatic
system; and activated lymphocytes would have easier accessibility to the tumor.

An appropriate step in experimental

studies would be an investigation of the leukocytic infiltrate around the tumor at sacrifice.

This, however, was not

investigated in this experiment.
Suggestions have also been made that the fibrin deposition plays both a nutritional role and a structural role
(Dvorak et al., 1979a; Zacharski et al., 1979).

Absence of

the fibrin could result in the inability to maintain adequate
nutrition and lack of a framework upon which tumor cells can
grow.

Fibrin formation and neovascularization have been

closely associated, and an alteration in fibrin cocoon formation may effectively change tumor vascularization and consequently growth (Lock, 1971; Dvorak et al., 1979a).

Our

results confirm a concomitant reduction in both tumor growth
and vascularization with warfarin, further supporting evidence
of a relationship between the two factors.
The suggestions that warfarin's anticoagulative activity
and resultant reduction in fibrin formation is the mechanism
causing reduced tumor growth could be further investigated
through the concurrent administration of warfarin and vitamin K.

In this situation, vitamin K would counteract war-

farin's activity and allow adequate clotting protein synthesis
for the ultimate development of fibrin.

It would be expected

that warfarin sodium administration, accompanied by vitamin K,
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would permit fibrin encasement of the tumor and growth comparable to tumor growth in control animals.

This hypothesis

has been tested by Brown using mice and examining tumor lung
colony development.

Results of Brown's experiments demon-

strated that mice receiving both warfarin and vitamin K had
no prolongation in prothrombin time and no reduction in
tumor lung colony formation (Brown, 1973).
The animals receiving low doses, 0.15 mgjkg, warfarin
sodium, exhibited intermediate values in whole blood clotting
time, the percent of original tumor mass, local vascularity,
vasodilation in the locale of the tumor, edema fluid, and
tumor attachment (Tables IV, V, VI and VII; Figures XII,
XIII, XIV).

These observations suggested a dose-response

relationship between warfarin and tumor growth and other
related factors.

In animals which received high dos~ war-

farin sodium, a more substantial level of anticoagulation was
achieved (Table IV, Figure XI).

If a dose-response relation-

ship may be suggested, the higher level of anticoagulation
would result in a greater inhibition of fibrin formation and
tumor investment.

In the animals dosed with 0.15 mgjkg

warfarin sodium, reductions in tumor growth and related
factors were observed to a lesser degree than in the high
dose animals. · These findings suggest that an intermediate
level of anticoagulation provided only a moderate decrease
in fibrin encasement of the tumor.
Observations in the animals receiving high doses of
warfarin sodium also revealed a significant reduction in the
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number of host blood vessels converging on the tumor and
also in vasodilation in the locale of the tumor (Table V,
Figure XIV).

Trends towards a reduction in vascularity,

which were not significant, were observed in the low dose
warfarin sodium group; and 92 percent of the animals in this
group showed the presence of

vasod~lation.

Again, these

findings suggest both a dose-response relationship and a
link between tumor vascularization and tumor growth.

Earlier

studies have suggested that vascularization of the tumor is
required for adequate nutritional maintenance and waste
disposal (Folkman, 1976; Gullino, 1978, 1981; Maugh, 1981).
Folkman has demonstrated that the absence of a blood supply
results in an abrupt cessation of tumor growth, leaving a
small dormant tumor mass ( 1976).

It has previo·usly been

suggested that the induction of anticoagulation results in
the reduction of tumor encasement by fibrin:

Dvorak has

linked the fibrin cocoon with neovascularization, stating
that vascular changes have been associated with fibrin cocoon
investment in line 10 guinea pig carcinomas (1979a).

An

editorial in the British Medical Journal has proposed that
the fibrin coat may possess angiogenesis-inductive capabilities (Lock, 1971).

Our findings are in agreement with these

many studies and lend evidence that the reduced fibrin coat
has potentiated a reduction in tumor vascularization.
As mentioned earlier, vascularization is necessary for
the advancement of a tumor mass from a dormant state to one
of progressive growth (Folkman, 1976).

The link between the
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degree of inhibition of vascularity and reduced tumor growth
is quite evident in the experiment presented.

The animals

which demonstrated greater reductions in tumor growth, those
of the high dose warfarin sodium group, had significant
reductions in tumor vascularity and local vasodilation
(Tables V, VI; Figure XIV).

It is possible that reduced

fibrin cocoon hindered the tumor's ability to stimulate and
incorporate host blood vessels to meet its metabolic requirements.

The reduced tumor growth, therefore, could be attri-

buted to either the host's ability to recognize and attack
the tumor or the failure of adequate vascularization to the
tumor.

A combination of these two mechanisms is also a

feasible postulation.

Mice anticoagulated with.a low dose

of warfarin sodium were found to have some reduction in both
tumor growth and vascularity.

The vascularity reduction was

not significant (Table V, Figure XIV).

Perhaps the moderate

tumor growth reduction may be linked to the moderate reduction of vessel proliferation in the area of the tumor.

In

this case, the tumor may have been able to meet some of its
metabolic needs through the minimal vasculature provided.
Statistically significant reductions in the degree of
attachment of the tumor were observed in the mice in both
the high dose and low dose warfarin sodium groups (Table V,
Figure XIII).

Again, the low dose warfarin sodium animals

demonstrated an intermediate level of attachment reduction.
One suggestion of the role of the fibrin cocoon has been
in the promotion of metastasis by providing assistance in
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the lodgement of metastasizing cells (Hagmar and Boeryd,
1969; Brown, 1973; Zacharski et al., 1979).

Experimental

and clinical examinations of certain mouse and human tumors
have demonstrated that the administration of agents with

.

anticoagulant activity can greatly reduce metastasis (Hagmar and Boeryd, 1969; Brown, 1973; Zacharski et al., 1981).
In our examinations a demonstration of anticoagulation accompanied by a significant reduction in tumor attachment is
seen.

This may serve as further evidence that a reduction·

in fibrin formation around the tumor has occurred in the
anticoagulated animals.

It may also provide supporting

evidence that fibrin deposition may indeed be important in
aiding the attachment of metastasizing tumor cells.
Examination of whole blood clotting _times reveals a
large amount of variability in clotting times; yet, the high
dose warfarin sodium animals still show a significant prolongation in whole blood clotting times (Table IV, Figure XI).
This phenomenon is not unique to this experiment.

There

have been other reports of the inability to maintain a
steady serum level of this anticoagulant (Brown, 1973).
is further confirmed by several researchers investigating
warfarin sodium activity in mice and rats (Niedner, 1974,
1974a, 1974b; personal communications with Gerhard Levy).
Similar findings have been seen in earlier unpublished
observations in our laboratory.

This

CONCLUSION
From this study it has been observed that daily administration of· high doses of warfarin sodium in C3H/HeJ
female mice with mammary tumor implants leads to a statistically significant prolongation in whole blood clotting
times.

This extended clotting time is accompanied by a

statistically significant reduction in the percent of original tumor mas·s implanted when compared to control animals.
Likewise, significant reductions in local vascularity,
vasodilation, tumor attachment and edema fluid were noted
in the high dose experimental group.

These observations

have supported the postulation that tumor growth may be
effectively altered by decreasing fibrin formation.
Moderate reductions, lacking statistical significance,
were seen in the tumor growth of mice receiving low doses
of warfarin sodium.

Similarly, edema fluid, vasodilation,

and the number of blood vessels approaching the tumor showed
intermediate, and in some instances, significant reduction,
values in these mice.

The intermediate

values suggest that

a dose-response relationship exists between warfarin and
the tumor-related parameters.

An examination of the sig-

nificantly reduced attachment ratings observed in both of
the anticoagulated groups suggest that defibrination may
serve as a mechanism in the regulation of tumor metastasis
(Hagmar, 1969; Brown, 1973; Zacharski, 1979).
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Relationships between altered fibrin formation around
the tumor, anticoagulant administration, and vascularization
may serve to demonstrate a single major conclusion.

Our

experimental observations support the suggestion that the
fibrin investment serves an important role in the establishment of a vascular supply to the tumor which is vital for
its establishment, survival, and growth.

REFERENCES
1965.
Inbred Strains of Mice Number 4: Companion
Issue to Mouse News Letter Number 33. Jax Labs, Bar
Harbor, Maine.
.. 1969.
Inbred Strains of Mice Number 6: Companion
Issue to Mouse New~ Letter Number 41. Jax Labs, Bar
Harbor, Maine.
1973.
Inbred Strains of Mice Number 8: Companion
Issue to Mouse News Letter Number 49. Jax Labs, Bar
Harbor, Maine.
1977.
Inbred Strains of Mice Number 10: Companion
Issue to Mouse News Letter Number 57. Jax Labs, Bar
Harbor, Maine.
1967. Standards for the Breeding, Care and Management of Laboratory Mice: General Considerations.
Institute of Laboratory Animal Resources, National
Research Council.
Auerbach, R. , Kubai, L. , and S idky, Y. , 1976. Angiogenesis
Induction by Tumors, Embryonic Tissues, and Lymphocytes.
Cancer Research 36:
3435-3440.
Banaja, M., 1982. The Effect of Heparin on Growth Characteristics of Transplanted Spontaneously Occurring Mouse
Mammary Tumor. University of the Pacific, Stockton, CA.
Becker, F., 1977. Cancer Volume 6: A Comprehensive Treatise:
Radiotherapy, Surgery, and Immunotherapy. Plenum Press,
New York.
Brown, J., 1973. A Study of the Mechanism by Which Anticoagulation with Warfarin Inhibits Blood-borne Metastases.
Cancer Research 33: 1217-1224.
Busch, H. (editor), 1974. The Molecular Biology of Cancer.
Academic Press, New York.
Chodak, G., Haudenschild, C., Gittes, R., and Folkman, J.,
1980. Angiogenic Activity as a Marker of Neoplastic and
Preneoplastic Lesions of the Human Bladder. Ann. Surg.
192: 762-771.
--

75

76
Cliffton, E. and Agostino, D., 1965. The Effects of Fibrin
Formation and Alterations in the Clotting Mechanism on
the Development of Metastases. Vase. Dis. 2:
43-52.
DeMeo, R., 1982. Anticoagulation Therapy Lecture Handout
for Continuing Education. University of the Pacific
School' of Pharmacy.
Devlin, T. (editor), 1982. Textbook of Biochemistry with
Clinical Correlations. John Wiley and Sons, New York.
Dvorak, H., Orenstein, N., Carvalho, A., Churchill, W.,
Dvorak, A., Galli, S., Feder, J., Bitzer, A., Rypysc, J.,
and Giovinco, P., 1979.
Induction of a Fibrin-Gel
Investment: An Early Event in Line 10 Hepatocarcinoma
Growth Mediated by Tumor-Secreted Products.
Journal of
Immunology 122: 166-174.
Dvorak, H., Dvorak, A., Manseau, E., Wiberg, L., and
Churchill, W., 1979a. Fibrin Gel Investment Associated
with Line 1 and Line 10 Solid Tumor Growth, Angiogenesis,
and Fibroplasia in Guinea Pigs. Role of Cellular
Immunity, Myofibroblasts, Microvascular Damage, and
Infarction in Line 1 Tumor Regression. JNCI 62:· 14591466.
Dvorak, H. , Quay S. , Orenstein, N. , Dvorak, A. , Hahn, P. ,
and Bitzer, A. , 1981. Tumor Shedding and eoagula t ion.
Science 212:
923-924.
Folkman, J., 1974.
19:
331-358.

Tumor Angiogenesis.

Adv. Cancer Research

Folkman, J., 1975. Tumor Angiogenesis: A Possible Control
Point in Tumor Growth. Annals of Internal Medicine 82:
96-100.
Folkman, J., 1976.
American 234:

The Vascularization of Tumors.
59-74.

Folkman, ·J., and Haudenschild, C., 1980.
vitro. Nature 288:
553-556.

Scientific

Angiogenesis in

Foulds, L., 1969. Neoplastic Development Volume 1.
Press, New York.

Academic

Foulds, L., 1975. Neoplastic Development Volume 2.
Press, N~w York.

Academic

Gilman, A., Goodman, L., and Gilman, A., (editors), 1980.
Goodman and Gilman's: The Pharmacological Basis of
Therapeutics. Sixth Edition.
Macmillan Publishing Co.,
Inc., New York:'

77
Gimbrone, M., Cotran, R., Leapman, S., and Folkman, J., 1974.
Tumor Gro~th and Neovascularization: An Experimental
Model Using the Rabbit Cornea. JNCI 52:
413-419.
Goerner, A., 1930. The Influence of Anticlotting Agents on
Transplantation and Growth of Tumor Tissue. The Journal
of Laboratory and Clinical Medicine 16: 369-372.Green, E. (editor), 1966. Biology of the Laboratory Mouse.
Second Edition. McGraw-Hill, New York.
Green, I., Cohen, S., and McCluskey, R., (editors), 1977.
Mechanisms of Tumor Immunity. John Wiley and Sons,
New York.
Gullino, P., 1981. Angiogenesis and Neoplasia.
Journal of Medicine 305:
884-885.

New England

Gullino, P., 1978. Angiogenesis and Oncogenesis:
Editorial. JNCI 61:
639-643.

Guest

Guyton, A., 1981. Textbook of Medical Physiology. Sixth
Edition. W. B. Saunders Company, Philadelphia.
Hagmar, G., and Boeryd, B., 1969. Distribution of intravenously induced metastases in heparin- and coumarintreated mice. Path. Europ. !: . 103-111.
Hilgard, V., and Thornes, R., 1976. Anticoagulants in the
Treatment of Cancer. European Journal of Cancer 12:
755-762.
Hiramoto, R., Bernecky, J., Jurandowski, J., and Pressman, D.,
1960. Fibrin in Human Tumors. Cancer Research 20:
592-598.
Hyde, R., and Patnode, R., 1978.
Immunology.
lishing Company, Inc., Reston, Virginia.

Reston Pub-

Isselbacher, K., Adams, R., Braunwald, E., Petersdorf, R.,
and Wilson, Jr., (editors), 1980. Harrison's Principles
of Internal Medicine. Ninth Edition. McGraw-Hill,
New York.
Karnofsky, D., 1948. The Basis for Cancer Chemotherapy.
Stanford Medical Bulletin 6:
257-269.
Knapp, K., Banaja, M., Deweese, J., and Young, S., 1981.
Effects of heparin on C3HjHeJ mouse mammary tumor growth
and morphology. Anat. Res. 199: 144A.
Koller, P., 1960. Chromosome Behavior in Tumors: Readjustments to Boveri's ~heory. Cell Physiology of Neoplasia.
University of Texas Press, Austin.

78
Lock, S. (editor), 1971. Fibrin and Cancer.
Journal 4:
641-642.

British Medical

Maugh, T. , 1981. Angiogenesis Inhibitors Link Many Diseases.
Science 212:
1374-1375.
Niedner, V., Kayser, M., and Meyer, F., 1974. Rodentizide
Wirkung von Warfarin 1. Mitteilung: Eniflub auf
die Blutgerinnung. Arzneimittel-Forschung (Drug
Research) 24: 802-806.
Niedner, V., 1974a. Rodentizide Wirkung von Warfarin 2.
Mitteilung: Kinetik. Arzneimittel-Forschung (Drug
Research) 24: 922-924.
Neidner, V., Oettingen, U., Kayser, M., and Meyer, F., 1974b.
Rodentizide Wirkung von Warfarin 3: Mitteilung:
Bindung au Serumproteine. Arzneimittel-Forschung
(Drug Research) 24:
1039-1043.
O'Reilly, R., Pool, J., and Aggeler, P., 1968. Hereditary
Resistance to Coumarin Anticoagulant Drugs in Man and
Rat. Annals of the New York Academy of Sciences 151:
913-931.
Poggi, A., Mussoni, L., Kornblihtt, L., Ballabio, E.,
DeGaetano, G., and Donati, M., 1978. Warfarin Enantiomers,
Anticoagulation, and Experimental Tumour Metastasis.
Lancet -1: 163-164.
Robbins, S., Angell, M., and Kumar, V., 1981. Basic Pathology.
Third Edition. W. B. Saunders Company, Philadelphia.
Ryan, J., Ketcham, A., and Wexler, H., 1968. Reduced Incidence of Spontaneous Metastases with Long-term Coumadin
Therapy. Annals of. Surgery 168:
163-168.
Ryan, J., Ketcham, A., and Wexler, H., 1969. Warfarin
Therapy as an Adjunct to the Surgical Treatment of
Malignant Tumors in Mice. Cancer Research 29:
2191-2194.
Sebrell, W. and Harris, R., 1954. The Vitamins:
Chemistry,
Physiology, Pathology Volume II. Academic Press Inc.,
New York.
Smith, L. and Thier, S. (editors), 1981. Pathophysiology:
The Biological Principles of Disease. W. B. Saunders
Company, Philadelphia.
Smith, R. and Landy, M. (editors), 1975.
Immunobiology of
the Tumor-Host Relationship. Proceedings of an International Conference Held at the Sormani Palace Milan,
Italy. Academic Press, New York.

79
Snyderman, R., Pike, M., Blaylock, B., and Weinstein, P.,
1976. Effects of Neoplasms on Inflammation: Depression
of Macrophage Accumulation After Tumor Implantation.
Journal of Irmnunology 116: 585-589.
Stanford, C., 1979. Anticoagulants in the treatment of
small cell carcinoma of the bronchus. Thorax 34:
113-116 ..
Suttie, J., 1979. How coumarin anticoagulants work.
Therapy 9:
63-71.
Thornes, R., 1972. Fibrin and Cancer.
Journal 1:
110-111.
Vigran, T., 1965.
and Febiger,

Drug

British Medical

Clinical Anticoagulant Therapy.

Lear

Philadelph~a.

Wattenberg, L., Lan, L., and Fladmoe, A., 1979.
Inhibition
of Chemical Carcinogen-induced Neoplasia by Coumarins
and a-Angelicalactone. Cancer Research 39: 1651-1654.
Wormser, H., 1978. Pharmacology of anticoagulant, Antithrombotic and Thrombolytic Drugs. Hospital Pharmacy
13: 438-444.
Zacharski, L., 1979. Rationale and Experimental Design for
the VA Cooperative Study of An~icoagulation (Warfarin)
in the Treatment of Cancer.
Cancer 44:
732-741.
Zacharski, L., 1981. Effect of Warfarin on Survival in
Small Cell Carcinoma of the Lung. JAMA 245: 831-835.

